Innovative DNA Immunotherapies

2

Mission

To develop and commercialize an anti-inflammatory DNA technology which

has the potential to treat diseases such as Type 1 Diabetes, Multiple Sclerosis,

Lupus, Rheumatoid Arthritis, Asthma and allergies.

3

Problem

Inflammatory Disorders

Example: Autoimmune diseases

24 million people in U.S.

↑ 3-5% rate

4

Current approaches to control inflammation can

cause infections and cancers

5

Control unwanted inflammation

Specifically and safely

ADI

Solution

6

Next generation DNA immunotherapy

Natural control of inflammation

Programmable and versatile

Teaches body to distinguish between friendly and dangerous cells

Apoptotic DNA Immunotherapy (ADI)

7

2-3 million people in U.S.

Type 1 Diabetes

NOD mice develop autoimmune (type 1) diabetes between ages of 11 – 21 weeks

Observe until 40 weeks old

1 DNA injection / week for 8 weeks

ADI

8

ADI Treatment of T1D

Untreated ADI Treated

No diabetes during treatment 80% lasting response

9

ADI for Skin Graft

Lost graft Graft survived Hair growth

10

Competition in T1D Differentiating Points

SEKRIS Diamyd Andromeda Other DNA

Safe Repeated Delivery + - - +

Immune Modulators 3 1 2 1

Tolerogenic Apoptosis + - - -

Impacts Key Immune Cells

+ - - -

11

Competitive Advantages 1. ADI does not rely on a single mechanistic approach. Each

component affects different arms of the immune system. 2. ADI activates key immune cells known to maintain tolerance in

both mice and humans. 3. ADI has been successfully applied to 2 different models of

inflammatory disorders: Type 1 diabetes and skin allografts. 4. ADI is plasmid DNA-based and expected to be safe. 5. ADI can be safely and repeatedly administered to achieve its full

potential therapeutic effect thereby increasing its potency for more aggressive inflammatory conditions.

6. ADI is a DNA-based product that will be administered in very small quantities and is cost effective.

12

Team CEO/President

Shahrokh Shabahang, DDS, MS, PhD

CMO

Joachim-Friedrich Kapp, MD, PhD

Clinical Advisors

Alan Garber, MD, PhD

Peter Gottlieb, MD

Joachim-Friedrich Kapp, MD, PhD

Gerald Nepom, MD, PhD

Mark Peakman, MSc, PhD

Jay Skyler, MD, MACP

Gen Counsel/Assistant Board Secretary

Jan Sundberg, JD

Legal Advisors

James Hill, MD, JD MWE (IP)

The Eclipse Group (Corporate and Securities)

Acting CFO

David Chariton, MA

Accounting Advisor

Kelly Allen & Associates (CPA)

CSO

Leonard Bailey, MD

Science Advisors

Leonard Bailey, MD

Gilles Benichou, PhD

John Rossi, PhD

Daniel Salomon, MD

Roland Tisch, PhD

Business Advisors

Charles Crocker, MBA

Neil Desai, PhD

13

Timeline

Year 2 Year 1

ADI Technology

Clinical Program for

T1D in Germany

GMP Manufacturing

(Aldevron)

Meeting with PEI

Tox Plan (LPT)

Initiation of C.T.s

Transplantation Program

Collaboration with Gilles Benichou at MGH

Manufacturing Licensing

Opportunity with Bacterial Strain

14

Budget Operating Expenses Year 1 Year 2

R&D at MGH/Harvard Transplant Labs $132,000 $132,000 Intellectual Property $120,000 $120,000

Personnel $316,410 $316,410 GMP Manufacturing $250,000 $0

Licensing Fees to Loma Linda University $149,000 $25,000 GLP Safety/Toxicology Studies $375,000 $375,000

Legal $60,000 $60,000 Accounting $18,000 $18,900

Regulatory - IND Submission $0 $55,000 Milestone Payments to Loma Linda University $75,000 $100,000

Office Expenses $91,200 $94,350 Total Operating Expenses $1,646,610 $1,236,660

15

Potent, safe and patient friendly

Impactful

Platform to build an industry

Game changing platform technology